# Immune & Thymic Peptide FAQ — KPV and Thymulin — Peptide HC > Frequently asked questions about two Immune & Thymic research peptides — KPV and Thymulin — answered from the peer-reviewed literature, with citations. Direct, citation-anchored answers to the questions readers most often bring to KPV and Thymulin. ## What is KPV peptide? KPV is a linear tripeptide — three amino acids: lysine, proline, valine — that corresponds to residues 11-13, the C-terminal sequence, of alpha-melanocyte-stimulating hormone (alpha-MSH). Its systematic name is L-lysyl-L-prolyl-L-valine, and it is also catalogued as alpha-MSH(11-13). The peptide is a research chemical with no approved drug or dietary supplement status [3][5]. ## What does KPV peptide do? In cell and animal research, KPV primarily functions as an anti-inflammatory agent. It is taken up into intestinal epithelial cells by the PepT1 transporter and suppresses NF-kB and MAP-kinase signaling inside those cells, reducing production of pro-inflammatory cytokines such as IL-1beta and TNF-alpha [3]. In mouse colitis models, oral KPV reduced disease severity, lowered inflammatory infiltrate, and accelerated recovery [4]. It also accelerated corneal wound healing in a rabbit model, through a nitric-oxide-dependent mechanism [6]. No human clinical trials of KPV have been published [3]. ## What is KPV peptide used for? In laboratory research, KPV is studied primarily as a model for anti-inflammatory signaling in the gut. The most extensive body of work concerns chemically induced colitis in mice, where it has reduced mucosal damage and inflammatory markers via PepT1-mediated uptake [3][4]. Researchers also study it as a building block for targeted drug-delivery formulations, because the PepT1 transporter it uses is upregulated in inflamed tissue, making KPV a potential targeting handle for drugs that need to reach inflamed intestine [1][2]. It is not used clinically in any approved context. ## What is KPV peptide good for? According to the published research, KPV's strongest signal is in calming intestinal inflammation in animal models. It consistently reduced colonic disease severity, inflammatory infiltrate, and myeloperoxidase activity in mouse colitis studies, including in a model using MC1R-deficient mice, confirming the anti-inflammatory mechanism does not depend on melanocortin receptors [4]. A comprehensive review also lists protective effects in broader inflammatory models — skin, airway, eye, joints — though those are not as extensively studied for this specific peptide [5]. All findings are preclinical; KPV is not approved for any therapeutic use. ## What is thymulin? Thymulin is a nonapeptide (nine-amino-acid peptide) hormone produced exclusively by the epithelial cells of the thymus gland. Its sequence is pyroGlu-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn. It is also known as serum thymic factor (FTS, from the French *facteur thymique serique*). Critically, thymulin is biologically active only when bound to one zinc ion per molecule; the zinc-free form has no documented immune activity [12]. ## What is thymulin peptide? Thymulin peptide is the zinc-dependent nonapeptide hormone whose primary documented role is driving T-lymphocyte differentiation and maturation within the thymus. It also functions as a hypophysiotropic signal — acting on the anterior pituitary to influence hormone release — and exerts anti-inflammatory effects in peripheral and central models. Its production by the thymus declines with age and with zinc deficiency; serum thymulin activity is used as a biomarker of zinc status [12]. It is a research peptide with no approved human therapeutic use [9]. ## Is thymulin the same as serum thymic factor (FTS)? Yes. Thymulin and serum thymic factor (FTS) are the same molecule. "FTS" is the earlier name, drawn from the original French designation *facteur thymique serique*, used in much of the older literature. "Thymulin" became the preferred name as the peptide's sequence and zinc-dependence were established. The two names are interchangeable, and the zinc-bound active form is sometimes specifically designated Zn-thymulin or FTS-Zn [12]. ## How is thymulin different from thymosin alpha-1? Thymulin and thymosin alpha-1 are completely distinct molecules with different sequences, sizes, mechanisms, and regulatory histories. Thymulin is a nonapeptide (nine amino acids) produced by thymic epithelial cells whose activity requires bound zinc and whose primary role is T-cell differentiation and the thymus-neuroendocrine axis [11]. Thymosin alpha-1 is a 28-amino-acid peptide derived from a larger precursor protein (prothymosin alpha) that has been developed as a pharmaceutical (Zadaxin, thymalfasin) for specific immune indications in some countries. They share a thymic connection in that both are associated with thymic function, but they have no structural relationship and should not be substituted for one another. Also distinct: thymosin beta-4 (the parent of TB-500), thymopentin, and thymalin (a bovine thymic complex) [11]. ## Can KPV and Thymulin be compared directly? In structural terms, no — one is a tripeptide fragment of a melanocortin hormone, the other is a zinc-bound nonapeptide hormone of the thymus. Their research questions are also different: KPV is studied for peripheral anti-inflammatory signaling at tissue sites, while thymulin is studied for central T-cell programming and the thymus-neuroendocrine axis [3][9]. They share the feature of having no human clinical trial data, being preclinical research compounds, and having anti-inflammatory activity (through different mechanisms). The [comparison page](/compare) lines them up side by side on the dimensions that matter most for reading the research. ## Are there any human trials of these peptides? No published human clinical trials exist for KPV in any form [3]. For thymulin, the clinical literature is sparse: some biochemical studies in humans (measuring serum thymulin activity as an indicator of zinc status) exist, and a handful of studies used synthetic analogs rather than native thymulin itself, but no completed randomized controlled trials of native thymulin as a therapeutic agent appear in the public record [9][12]. Both compounds are research-stage only. ## Do either of these peptides have WADA doping implications? KPV is not specifically listed by name on the WADA Prohibited List, but as a non-approved peptide it should be treated cautiously in any sport context — the S0 category (non-approved substances) covers unapproved pharmacological substances generally [3]. Thymulin is also not specifically listed; peptide hormones and immunomodulators are categories of particular scrutiny in anti-doping programs, and its status should not be asserted as definitively permitted [9]. Any competitive athlete subject to anti-doping rules should consult with their anti-doping authority before any research-compound exposure. --- A literature digest on immune and thymic research peptides — study summaries with citations, not prescriptions.